(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
7 August 2014 (07.08.2014)

WIPO | PCT

(10) International Publication Number
WO 2014/121221 A8

(51) International Patent Classification:
C07K 16/26 (2006.01) *A61K 31/395* (2006.01)
C07K 16/00 (2006.01)

(21) International Application Number:
PCT/US2014/014490

(22) International Filing Date:
3 February 2014 (03.02.2014)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/759,961 1 February 2013 (01.02.2013) US
61/815,220 23 April 2013 (23.04.2013) US

(71) Applicants: **SANTA MARIA BIOTHERAPEUTICS, INC.** [US/US]; 3260 Bayshore Blvd., Brisbane, CA 94005 (US). **AMGEN INC.** [US/US]; One Amgen Center Drive, Thousand Oaks, CA 91320 (US).

(72) Inventors: **HAN, Huiquan**; c/o Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA 91320 (US). **HAQQ, Christopher, Michael**; c/o Santa Maria Biotherapeutics, Inc., 3260 Bayshore Blvd., Brisbane, CA 94005 (US). **CIECHANOVER, Isaac**; c/o Santa Maria Biotherapeutics, Inc., 3260 Bayshore Blvd., Brisbane, CA 94005 (US). **ZHOU, Xiaolan**; c/o Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA 91320 (US). **LU, John, Zhaonian**; c/o Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA 91320 (US).

(74) Agents: **KIM, Jane, N.** et al.; Fenwick & West LLP, 801 California Street, Mountain View, CA 94041 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

(48) Date of publication of this corrected version:
16 April 2015

(15) Information about Correction:
see Notice of 16 April 2015

(54) Title: ADMINISTRATION OF AN ANTI-ACTIVIN-A COMPOUND TO A SUBJECT




FIG. 26

(57) Abstract: The present invention relates to methods of treating ovarian cancer in a subject by administering to the subject by evaluating the subject's expression levels of specific biomarkers or angiogenic an anti-activin-A compound, such as an anti-activin-A antibody or an activin-A-binding receptor. In some embodiments, at least two compounds are administered to the subject, where the first compound is an anti-activin A compound, and the second compound is a chemotherapeutic compound, for example capecitabine.The invention further relates to methods of identifying subjects for treatment factors.

WO 2014/121221 A8